臨床泌尿器科72巻6号

2018年05月発行

特集 副腎疾患の基礎と臨床─最前線を知る

〈臨床〉

副腎皮質癌の最新の知見

著者： 馬越洋宜¹ 成瀬光栄¹ 田上哲也¹

所属機関： ¹京都医療センター内分泌・代謝内科

ページ範囲：P.484 - P.489

文献概要

▶ポイント

・治療の要は熟練した外科医による初回手術時における腫瘍の完全切除である．

・切除不能例においては，エトポシド，ドキソルビシン，シスプラチン＋ミトタン（EDP-M）併用療法を行う．

・年間15例以上の副腎腫瘍の手術実績を有し，副腎皮質癌の診療体制の整った医療施設での治療が推奨される．

参考文献

1） Norton JA : Adrenal tumors. In : DeVita VT Jr, Hellman S, Rosenberg SA, eds : Cancer : Principles and Practice of Oncology. 7th ed, pp1528─1539, Lippincott Williams & Wilkins, Illinois, 2005

2） Luton JP, Cerdas S, Billaud L, et al : Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322 : 1195─1201, 1990

3） Fassnacht M, Kroiss M and Alloli B : Update in Adrenocortical Carcinoma. J Clin Endocrinol Metab 98 : 4551─4564, 2013

4） Beuschlein F, Weigel J, Saeger W, et al : Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100 : 841─849, 2015

5） Polat B, Fassnacht M, Pfreundner L, et al : Radiotherapyin adrenocortical carcinoma. Cancer 115 : 2816─2823, 2009

6） Sabolch A, Feng M, Griffith K, et al : Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Physics 80 : 1477─1484, 2011

7） Habra MA, Ejaz S, Feng L, et al : A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98 : 192─197, 2013

8） Erdogan I, Deutschbein T, Jurowich C, et al : The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 98 : 181─191, 2013

9） Schteingart DE, Doherty GM, Gauger PG, et al : Management of patients with adrenal cancer : recommendations of an international consensus conference. Endocr Relat Cancer 12 : 667─680, 2005

10） Cazejust J, De Baère T, Auperin A, et al : Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 21 : 1527─1532, 2010

11） Ripley RT, Kemp CD, Davis JL, et al : Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol 18 : 1972─1979, 2011

12） Fassnacht M, Terzolo M, Allolio B, et al : Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366 : 2189─2197, 2012

13） Khan TS, Imam H, Juhlin C, et al : Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients : long-term survival in its adjuvant use. Ann Oncol 11 : 1281─1287, 2000

14） Sperone P, Ferrero A, Daffara F, et al : Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma : a multicenter phase II study. Endocr Relat Cancer 17 : 445─453, 2010

15） Gaujoux S and Mihai R ; joint working group of ESES and ENSAT : European Society of Endocrine Surgeons （ESES） and European Network for the Study of Adrenal Tumours （ENSAT） recommendations for the surgical management of adrenocortical carcinoma. Br J Surg 104 : 358─376, 2017

16） Reibetanz J, Jurowich C, Erdogan I, et al : Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 255 : 363─369, 2012

17） Henning JEK, Deutschbein T, Altieri B, et al : Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma : A Multicenter Study of Efficacy and Predictive Factors. J Clin Endocrinol Metab 102 : 4323─4332, 2017

18） Lalli E and Luconi M : The next step : mechanisms driving adrenocortical carcinoma metastasis. Endocr Relat Cancer 25 : R31─R48, 2018

19） Salvianti F, Canu L, Poli G, et al : New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. Oncotarget 8 : 65525─65533, 2017

20） Creemers SG, Korpershoek E, Atmodimedjo PN, et al : Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma : A Case Series. J Clin Endocrinol Metab 102 : 3611─3615, 2017

21） Creemers SG, Hofland LJ, Korpershoek E, et al : Future directions in the diagnosis and medical treatment of adrenocorticalcarcinoma. Endocr Relat Cancer 23 : R43─69, 2016

22） Zheng S, Cherniack AD, Dewal N, et al : Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29 : 723─736, 2016

23） Fassnacht M, Berruti A, Baudin E, et al : Linsitinib （OSI-906） versus placebo for patients with locally advanced or metastaticadrenocortical carcinoma : a double-blind, randomised, phase 3 study. Lancet Oncol 16 : 426─435, 2015